Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242117 | 0.77 | OPRL1 (0.45) | OPRL1OPRM1 | |
| SCHEMBL241468 | 0.76 | OPRL1 (0.42) | OPRL1OPRM1 | |
| SCHEMBL243499 | 0.74 | AR (0.54) | PDE7AAKR1B1 | |
| SCHEMBL2699875 | 0.68 | P2RX7 (0.46) | — | |
| SCHEMBL3958965 | 0.65 | OPRL1 (0.45) | OPRL1OPRM1 | |
| SCHEMBL240013 | 0.65 | OPRL1 (0.62) | OPRL1OPRM1 | |
| SCHEMBL29932228 | 0.65 | ALDH1A1 (0.61) | — | |
| SCHEMBL31442447 | 0.64 | ALDH1A1 (0.51) | CCR2CCR1CCR5 | |
| SCHEMBL10911510 | 0.64 | ALDH1A1 (0.51) | CCR2CCR1CCR5 | |
| SCHEMBL31713613 | 0.64 | ROCK2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| EP-2121624-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008092878-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092878-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | OPRL1 263/4885OPRM1 554/4885PDE7A 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.